DUBLIN, July 28 — CroíValve, a clinical-stage medical device company developing the DUO™ transcatheter tricuspid coaptation valve system, today announced the appointment of Jaime Wheeler, MBA, CPhT, as Chief Executive Officer. In conjunction with this, Lucy O’Keeffe will transition into the role of Chief Operating Officer where she will support Jaime in delivering CroíValve’s mission of innovating a better way to treat tricuspid regurgitation (TR). Jaime is a transformational healthcare executive with more than 25 years of experience driving innovation at the intersection of clinical excellence and business strategy. Previously, Jaime served as the Senior Vice President of Global Clinical Affairs, Transcatheter Heart Valves at Edwards Lifesciences. There, she was instrumental in bringing multiple breakthrough therapies to market.
CroíValve recently announced the expansion of its TANDEM II study, a US and EU based prospective, multicenter study to evaluate the safety and performance of the DUO™ Adapt System in patients with severe or greater symptomatic TR.
Bernard Collins, Chairman of CroíValve, commented: “Jaime brings a proven track record in guiding innovative technologies to market, along with leading high-performing teams. Her leadership will be hugely beneficial in guiding the company through its commercialization journey ahead as we expand our US base and global activities. I would like to thank Lucy, on behalf of the board of directors, for her dedication in leading CroíValve successfully through development and initial clinical validation, demonstrating the value proposition of the DUO System.”
Jaime Wheeler, newly appointed CEO, commented: “What drew me to CroíValve is the caliber of the team and the strength of the science behind the DUO System. I’ve built my career on bringing challenging, innovative technologies to patients, and I’m looking forward to doing that here, for our investors and, more importantly, for the patients living with tricuspid regurgitation.”
Lucy O’Keeffe, newly appointed COO, former CEO and Board member, added: “As CroíValve looks towards commercialization, it is the appropriate time to bring in a leader with the right experience for this next phase. Jaime’s exceptional track record of successfully bringing novel transcatheter devices to market is a tremendous asset for CroíValve. I am thrilled to collaborate with her as we embark on this exciting next chapter, accelerating our mission to deliver the DUO System to the patients who need it most.”